Analyst Price Target is $40.75
▲ +136.92% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Day One Biopharmaceuticals in the last 3 months. The average price target is $40.75, with a high forecast of $50.00 and a low forecast of $34.00. The average price target represents a 136.92% upside from the last price of $17.20.
Current Consensus is
The current consensus among 6 investment analysts is to moderate buy stock in Day One Biopharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.